The November 2018 issue of Pharmafocus is available to read online now!
pharmafile | November 6, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EU, President trump, Trump, anti vaxxer, brexit, clinical trials, opioid crisis, opioids, pharma, vaccines
As the US continues to battle the demons in its healthcare system, Donald Trump looks like he may finally make good on his numerous and repeated promises to bring down drug prices, as well as bring tangible action to the ongoing opioid crisis.
Since announcing a state of emergency over the latter crisis last year, the President has not been seen to attempt to affect any change on the issue, but hopes are high with the recent signing of a bipartisan bill which includes 200 provisions to tackle it, including partnerships with JJ&J, Facebook, Amazon and Google.
On the pricing front, Trump announced new plans to introduce an international pricing index as a reference point when setting new drug prices, in an attempt to bring the US’ costs more in line with the rest of the world. To be trialled in certain parts of the country next year, it could mark an important first step in correcting the runaway problem, but the industry has made its opposition to the strategy clear. Read the full story on our front page.
As Brexit becomes uncomfortably close and still absent of any certainty for public or industry, the former have been warned they may have to personally stockpile medications and AstraZeneca announced that it has halted its investments in the UK. You can read more about these repercussions on page 5, while on page 6, you can find similar warnings that caution that the UK’s divorce from the EU could severely impact research projects between the two.
Be sure not to miss our full-length features examining the EU’s clinical reporting problem, following the shocking news that half of all trial results go unreported in the region, and the threat that vaccine scepticism poses to patient adhere and public health. We also have a special feature from Herbert Smith Freehills on the impact blockchain is poised to make on healthcare and pharma, as well as an interview with Lund University and Insitut Laue-Langevin researchers on Galectin-3, the protein which could open up a raft of opportunities in diabetes, heart disease and breast cancer.
The new November issue of Pharmafocus is available to read online now!
Related Content
Merck plans to conduct trials for HPV vaccines
Merck, known as MSD outside of the US and Canada, has announced that it is …
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
Measles: the UK’s next epidemic?
Recently, the UK has seen a rapid increase in the number of cases of measles, …
